ArticleThe Journal of infectious diseases2014
Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease.
Article in The Journal of infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 1 synthesis or guideline pooled it.
- BCSH/BSBMT/UK clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation.British journal of haematology · 2016Guideline
- A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
- A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
- Risk Factors for Parainfluenza Virus Lower Respiratory Tract Disease after Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Trial
- Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Trial
- First Report on Remdesivir Use for the Treatment of Respiratory Syncytial Virus in Five Allogeneic Hematopoietic Cell Transplant Recipients.The Journal of infectious diseases · 2026Article
- Burden and Risk Factors for Severe Respiratory Syncytial Virus Infection among Pediatric Hematopoietic Cell Transplant Recipients.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Respiratory Syncytial Virus Hospitalizations in Adults ≥50 Years of Age and Those With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations, 2018-2020.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Observational
- Respiratory Syncytial Virus After Chimeric Antigen Receptor T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Respiratory Syncytial Virus in Hematopoietic Cell Transplant Recipients: Clinical and Humoral Risk Factors for Infection.Open forum infectious diseases · 2026Article
- The Impact of Pulmonary Hypertension on Hospitalization Risk in Adults with Respiratory Syncytial Virus Infection.Biomedicines · 2025Article
- Trends of respiratory viruses and factors associated with severe acute respiratory infection in patients presenting at a university hospital: a 6-year retrospective study across the COVID-19 pandemic.Frontiers in public health · 2025Article
- Relative Contribution of Diagnostic Testing to the Diagnosis of Respiratory Syncytial Virus in Hospitalized Adults in the United States.The Journal of infectious diseases · 2024Article
- Antiviral Stewardship in Transplantation.Viruses · 2024Review
- [Clinical characteristics and risk factors for death of respiratory syncytial virus infection in adult patients after hematopoietic stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- The Impact of Pretransplant Respiratory Virus Detection on Posttransplant Outcomes in Children Undergoing Hematopoietic Cell Transplantation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Identification of Lower Respiratory Tract Pathogens in Cancer Patients: Insights into Fatal Outcomes.Microorganisms · 2024Article
- Evolving Epidemiology of Pediatric Respiratory Syncytial Virus (RSV) Cases Around COVID-19 Pandemic: Impact and Clinical Insights, Retrospective Cohort Study.Journal of epidemiology and global health · 2024Article
- Respiratory Syncytial Virus Infections in Recipients of Bone Marrow Transplants: A Systematic Review and Meta-Analysis.Infectious disease reports · 2024Review
- Inter and intra-host diversity of RSV in hematopoietic stem cell transplant adults with normal and delayed viral clearance.Virus evolution · 2024Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) lower respiratory tract disease (LRD) is a life-threatening complication in hematopoietic cell transplant (HCT) recipients. Lymphopenia has been associated with an increased risk of progression from upper respiratory tract infection (URI) to LRD.
methodsThis study retrospectively analyzed the significance of lymphocyte engraftment dynamics, lung function, smoking history, corticosteroids, antiviral treatment, viral subtypes, and RSV-specific neutralizing antibodies for the progression to LRD in 181 HCT recipients with RSV URI.
resultsIn multivariable models, smoking history, conditioning with high-dose total body irradiation, and an absolute lymphocyte count (ALC) ≤100/mm(3) at the time of URI onset were significantly associated with disease progression. No progression occurred in patients with ALCs of >1000/mm(3) at URI onset. Lymphocyte engraftment dynamics were similar in progressors and nonprogressors. Pre- and posttransplant donor and posttransplant recipient RSV subtype-specific neutralizing antibody levels, RSV viral subtypes, and corticosteroids also were not significantly associated with LRD progression.
conclusionsHost and transplant related factors appear to determine the risk of progression to LRD more than viral factors. Dysfunctional cell-mediated immunity appears to be important in the pathogenesis of progressive RSV disease after HCT. A characterization of RSV-specific T-cell immunity is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.